Investigating how hypocretin affects opiate addiction and withdrawal
Role of hypocretin in opiate addiction and withdrawal
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA LOS ANGELES · NIH-10876399
This study is looking at how a brain chemical called hypocretin might affect people who are trying to recover from heroin addiction, focusing on how changes in this chemical during withdrawal could help us find better ways to ease symptoms and prevent relapse.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA LOS ANGELES (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-10876399 on ClinicalTrials.gov |
What this research studies
This research explores the role of hypocretin, a neuropeptide, in the context of opiate addiction and the withdrawal process. It examines changes in the brain's hypocretin-producing neurons in individuals with a history of heroin use, focusing on how these changes may contribute to addiction and relapse. The study utilizes both human data and animal models to understand the mechanisms at play, including the effects of long-term morphine administration on hypocretin levels. By investigating these neuronal changes, the research aims to identify potential therapeutic targets for reducing withdrawal symptoms and preventing relapse.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a history of opiate use or addiction, particularly those experiencing withdrawal symptoms.
Not a fit: Patients who have not used opiates or are not experiencing withdrawal symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that alleviate withdrawal symptoms and reduce the risk of relapse in individuals recovering from opiate addiction.
How similar studies have performed: Previous research has shown promising results in understanding the role of hypocretin in addiction, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
LOS ANGELES, UNITED STATES
- UNIVERSITY OF CALIFORNIA LOS ANGELES — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SIEGEL, JEROME M — UNIVERSITY OF CALIFORNIA LOS ANGELES
- Study coordinator: SIEGEL, JEROME M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.